Showing results (81-90 of 102) with videos related to
Sort By:
Pageof 11
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.American Journal of Physical Medicine & Rehabilitation|June 16, 2022
A Conversation Between Past and Present Chairs of the American Board of Physical Medicine and Rehabilitation: Four Decades of History and the Future of Board CertificationJohn F Ditunno, B Stanley Cohen, John L Melvin, et al.Journal of Comparative Effectiveness Research|February 17, 2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel diseaseNanhua Zhang, Chunyan Liu, Steven J Steiner, et al.Journal of Translational Medicine|April 17, 2012
Engaging basic scientists in translational research: identifying opportunities, overcoming obstaclesJennifer A Hobin, Anne M Deschamps, Richard Bockman, et al.The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.Arthritis Research & Therapy|June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritisStanley Cohen, Jean S Beebe, Vishala Chindalore, et al.Clinical Pharmacology in Drug Development|July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA PatientsTong Zhu, James Keirns, Corrie Howieson, et al.Pageof 11